Porosified silicon wafer structures impregnated with platinum anti-tumor compounds: Fabrication, characterization, and diffusion studies

Biomedical Microdevices

Volumn 2, Issue 4, 2000, Pages 265-272

  Li, Xin ^a   St John, John ^a   Coffer, Jeffery L ^a   Chen, Yandong ^b   Pinizzotto, Russell F ^b   Newey, Jon ^c   Reeves, Chris ^c   Canham, Leigh T ^c  

^a TEXAS CHRISTIAN UNIVERSITY   (United States)

^b Center for Advanced Research and Technology   (United States)

^c NONE   (United Kingdom)

Author keywords

Calcium phosphate; Carbo platin; Cis platin; Drug delivery; Porous silicon

Indexed keywords

EID: 0000057760     PISSN: 13872176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. K.D. Wise and K. Najafi, in VLSI in Medicine, N.G. Einspruch, and R.D. Gold, (eds), (Academic Press, New York, 1989), Chap. 10.
2. T.A. Desai, D.J. Hansford, L. Kulinsky, A.H. Nashat, G. Rasi, J. Tu, Y. Wang, M. Zhang, and M. Ferrari, Biomed. Microdevices 2, 11 (1999).
3. S.S. Stensas and L.J. Stensas, Acta Neuropathologica 41, 145 (1978).
4. D.J. Edell, V.V. Toi, and V.M. McNeil, IEEE Trans. Biomed. Engr. 39, 635 (1992).
5. (a) L.T. Canham, Adv. Mater. 7, 1003 (1995).
6. (b) L.T. Canham, J.P. Newey, C.L. Reeves, M.R. Houlton, A. Loni, A.J. Simons, and T.I. Cox, Adv. Mater. 8, 847 (1996).
7. (c) L.T. Canham, J.P. Newey, C.L. Reeves, D.O. King, P.J. Branfield, J.G. Crabb, and M.C.L. Ward, Adv. Mater. 8, 850 (1996).
8. The SynchroMed® infusion system from Medtronic, Inc.
9. J.D. Benjamin, A.L. Mears, and J.C. White, US Patent, 4,793,825 (1988).
10. I. Kaetsu, Y. Morita, A. Otori, and Y. Naka, Trans. Am. Soc. Artif. Int. Organs 85, 75 (1990).
11. J.T. Santini, M.J. Cima, and R.S. Langer, US Patent, 5,797,898 (filed 2 July 1996).
12. X. Li, J.L. Coffer, Y. Chen, R.F. Pinizzotto, J.P. Newey, and L.T. Canham, J. Am. Chem. Soc. 120, 11706 (1998).
13. M. Itokzu, M. Esaki, K. Yamamoto, T. Tanemori, and T. Kasai, J. Mater. Res.: Mater. Med. 10, 249 (1999).
14. C.J. Langer, Semin. Radiat. Oncol. 9, 108 (1999).
15. (a) G. Sersa, M. Cemazar and D. Miklavcic, Cancer Res. 55, 3450 (1995).
16. (b) G.A. Hofman, S.B. Dev and G.S. Nanda, IEEE Eng. Med. Biol. 1245 (1996).
17. B. Rosenberg, in Cisplatin: Its History and Possible Mechanisms of Action, A.W. Prestayko, S.T. Crooke, S.K. Carter (eds), (Academic Press, New York, 1980), Ch. 2, p. 9.
18. R.B. Weiss, Drugs 46, 360 (1993).
19. P.J. O'Dweyer, S.W. Johnson, and T.C. Hamilton, in Cancer; Principles and Practice of Oncology, V.T. De Vita, S.A. Rosenberg, S. Hellman (eds), (Lippincott-Raven, Philadelphia, 1996), Ch. 19, pp. 418-432.
20. E. Wong and C.M. Giandomenico, Chem. Rev. 99, 2451 (1999).
21. T. Kokubo, H. Kushitrani, S. Sakka, T. Kitsigi, and T. Yamamuro, J. Biomed. Mater. Res. 24, 721 (1990).
22. 2 Purge). Two sets of calibration standards were prepared: one using 5 ppb, 10 ppb, 20 ppb, 40 ppb, 50 ppb, and 0.1 ppm solutions and another with 3.75, 7.5, 15, 30, and 60 ppm Pt solution standards.
23. S.E. Millar and D.A. House, Inorg. Chim. Acta 166, 189 (1989).
24. D.P. Bancroft, C.A. Lepre, and S.J. Lippard, J. Am. Chem. Soc. 112, 6860 (1990).
25. A. Uchida, Y. Shinto, N. Araki, and K. Ono, J. Orthopedic Res. 10, 445 (1992).
26. M.K. Wolpert-Defilippes, in Cisplatin: Antitumor Activity of Cisplatin Analogs, A.W. Prestayko, S.T. Crooke, S.K. Carter (eds), (Academic Press, New York, 1980) Chap. 11, p. 183.